Board of Directors
Erik Holmlin Ph.D., M.B.A.
President and CEO, BioNano Genomics, Inc.
Erik Holmlin has two decades of experience in the life science and health care industries. He is currently President and CEO of BioNano Genomics, a commercial stage venture-backed startup leading the introduction of a proprietary platform for genome mapping based on single molecule detection of extremely long read lengths.
Before joining BioNano Genomics, he served as President and CEO of GenVault Corporation, a life science company bringing innovative solutions to biosample management. He also served as an entrepreneur in residence (EIR) at Domain Associates, LLC, a leading dedicated life science venture-capital firm. Prior to these roles, Erik was Chief Commercial Officer at Exiqon A/S.
In 2001 Mr. Holmlin led the formation of GeneOhm Sciences, Inc., for which, over a span of 5 years, he was Director of Chemistry, Senior Technology Director, Vice President of Technology and Business Development, and Vice President of Marketing. He orchestrated GeneOhm's acquisition in 2006 by Becton Dickinson and then served BD as Vice President of Marketing and Development.
Erik holds MBA degrees from the Haas School of Business at UC Berkeley and the Columbia University School of Business, a Ph.D. in chemistry from Caltech, and an AB degree in chemistry from Occidental College.
Shana Kelley Ph.D.
Founder and Chief Executive Officer, Xagenic
Shana founded Xagenic in 2010 to develop new solutions for rapid diagnostic testing. She holds a faculty appointment at the University of Toronto, and is an expert in the area of diagnostic technology development. Dr. Kelley was a co-founder of GeneOhm Sciences, a San Diego-based diagnostics company that was acquired by Becton Dickinson in 2005. She has been recognized with a variety of distinctions, including being named one of “Canada’s Top 40 under 40” and a NSERC E.W.R. Steacie Fellow. She has also been recognized with the Steacie Prize and was also named a “Top 100 Innovator” by MIT’s Technology Review.
Dion Madsen B.Comm., CFA
Senior Managing Partner, BDC Capital
Dion Madsen joined BDC Venture Capital in 2012 as Senior Managing Partner in the Healthcare Fund.
Dion brings over 15 years of senior management experience as a financial executive and venture investor, most recently as Founder and Managing Director of Physic Ventures, and as Managing Director of Unilever Technology Ventures, Unilever’s North American corporate venture fund. Prior to Unilever, Dion led Chiron Corporation’s investor communications, as Director of Investor Relations, and built a new strategy for the company’s $500M BioPharma business. Before moving to San Francisco, Dion spent five years as Partner of RBC Capital Partners’ Life Sciences Venture Fund, the first third-party capital fund in RBC Capital Partners’ history.
Dion is a founding member of C100, a select group of the top 100 Canadians in the San Francisco Bay area, and has sat on the boards of directors of many venture capital funds and companies in the pharmaceutical and health care industries. He has also held the roles of M&A Advisor, Strategic Consultant and CFO for a biotechnology company.
He currently sits on the Board of Directors of Interface Biologics and is a Board observer at Agrisoma Biosciences, Phemi Health Systems and Chromatin. He is also a selection committee member of the San Francisco Canadian Technology Accelerator.
Dion is a CFA® charterholder and has a Bachelor of Commerce in Finance and Marketing from the University of Saskatchewan.
Shermaine Tilley Ph.D., M.B.A.
Managing Partner, CTI Life Sciences Fund
Shermaine Tilley is a Managing Partner at CTI Life Sciences Fund, a Montreal-based venture capital fund investing across Canada as well as in the U.S..CTI LSF currently has $245 M under management, comprised of 2014 vintage Fund II that is open for investment as well as a 2006 vintage Fund I. Since joining CTI LSF at its inception in 2006, Shermaine has played a critical role in each of the investments made by the Fund, but particularly by leading investments in Medicago - acquired by Mitsubishi Tanabe for $357 M in 2013 - as well as those in Immunovaccine (TSX: IMV), Phemi, Xagenic and Zymeworks. She was also a board observer in Enobia that was acquired by Alexion in 2012 in the largest takeout of a private development-stage biotech for $1.1B, assuming all milestones are received.
Prior to joining CTI LSF in 2006, Dr. Tilley was Senior VP at Drug Royalty Corporation, the world's first private equity firm doing royalty transactions in the biotech/pharma space. At DRC (now DRI), Dr. Tilley played a leading role in closing 12 transactions totaling over $200 M in investments.
Before DRC, Dr. Tilley ran and managed a research laboratory, holding faculty positions at the NYU School of Medicine and Public Health Research Institute, NY, and on the PHRI Board of Directors. Concomitantly with her tenure at NYU School of Medicine and PHRI, she consulted for the NIH Small Business Innovation Research (SBIR) program in immunology and infectious disease for 10 years.
Dr. Tilley holds a Ph.D. in biochemistry from the Johns Hopkins University School of Medicine, an MBA from the University of Toronto, and is a member of the CFA Society of Toronto. She currently sits on the boards of Immunovaccine (TSX: IMV), Phemi, Xagenic, Zymeworks and BIOTECanada.
Jesse I. Treu Ph.D.
Partner, Domain Associates
Jesse has been a Partner of Domain since its inception in 1985. He has been a director of 37 early-stage healthcare companies, 23 of which have so far become successful public companies.
Present board memberships include Afferent Pharmaceuticals, Aldeyra Therapeutics, CoLucid Pharmaceuticals, RightCare Solutions, Sebacia, Tandem Diabetes Care, Veracyte and Xagenic. He has served as a Founder, President and Chairman of numerous venture stage companies.
Prior to the formation of Domain, Jesse was Vice President of the predecessor organization to The Wilkerson Group, and its venture capital arm, CW Ventures. While at CW Ventures, he served as President and CEO of Microsonics, a pioneer in computer image processing for cardiology. Previous to that, Jesse held executive positions at Technicon Instruments Corporation (now Siemens Medical Solutions Diagnostics) and at GE. He received his B.S. in physics from Rensselaer Polytechnic Institute and his M.A. and Ph.D. in physics from Princeton University.